New directions in thrombolytic therapy

Although current thrombolytic agents have proven their clinical benefit, the failure to rapidly reperfuse some patients and the persistent bleeding risk represent areas for improvement in therapy. In the past two years, the field has been advanced by the regulatory approval of agents with greater ea...

Full description

Saved in:
Bibliographic Details
Published in:Current Opinion in Pharmacology 2001-04, Vol.1 (2), p.164-168
Main Author: Toombs, Christopher F
Format: Article
Language:English
Subjects:
alfimeprase
alteplase
Animals
Arterial Occlusive Diseases - drug therapy
Catheterization, Central Venous - adverse effects
Catheterization, Central Venous - methods
Contraindications
Fibrin - metabolism
Fibrinolytic Agents - pharmacokinetics
Fibrinolytic Agents - pharmacology
Fibrinolytic Agents - therapeutic use
Graft Occlusion, Vascular - prevention & control
Humans
Metalloendopeptidases - pharmacokinetics
Metalloendopeptidases - pharmacology
Metalloendopeptidases - therapeutic use
Plasminogen Activators - pharmacokinetics
Plasminogen Activators - pharmacology
Plasminogen Activators - therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors
prourokinase
Recombinant Proteins - pharmacology
Recombinant Proteins - therapeutic use
reteplase
staphylokinase
Stroke - drug therapy
tenecteplase
thrombolysis
Thrombolytic Therapy - adverse effects
Thrombolytic Therapy - methods
tissue plasminogen activator
Tissue Plasminogen Activator - pharmacokinetics
Tissue Plasminogen Activator - pharmacology
Tissue Plasminogen Activator - therapeutic use
urokinase
Urokinase-Type Plasminogen Activator - pharmacology
Urokinase-Type Plasminogen Activator - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although current thrombolytic agents have proven their clinical benefit, the failure to rapidly reperfuse some patients and the persistent bleeding risk represent areas for improvement in therapy. In the past two years, the field has been advanced by the regulatory approval of agents with greater ease of administration, continued development of new agents and exploration of the use of more advanced antiplatelet therapies in combination with thrombolytic agents. Finally, a new class of directly acting fibrinolytic agents is available.
ISSN:1471-4892
1471-4973
DOI:10.1016/S1471-4892(01)00030-3